Levodopa: History and Therapeutic Applications
- PMID:28904446
- PMCID: PMC5586109
- DOI: 10.4103/aian.AIAN_241_17
Levodopa: History and Therapeutic Applications
Abstract
Levodopa - the aromatic amino acid L-3,4-dihydroxy phenylalanine has held the attention of neurologists and pharmacologists alike for more than half a century. Even though extensive research has been done across the globe in treatment of Parkinson's disease, with different molecules, none could replace the gold standard treatment or provide complete relief for the debilitated. Although research brought us better tips and tricks to modulate the dopamine blood levels to balance between the desired and deleterious effects, it could never replace the basic substrate. From simple oral preparation to more advanced treatment like duodenal dopa administration for better efficacy and compliance, L-dopa has sure undergone scrutiny and stayed strong as the fundamental neurotransmitter replacement therapy to pave path for many more new therapeutic strategies. So as a token of gratitude to the revolutionary agent and pioneers behind it, a trip down the memory lane is in order.
Keywords: Dopamine; history of levodopa; levodopa; newer levodopa.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
- Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.Lees AJ, Tolosa E, Olanow CW.Lees AJ, et al.Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8.Mov Disord. 2015.PMID:25488030Review.
- The medical treatment of Parkinson disease from James Parkinson to George Cotzias.Fahn S.Fahn S.Mov Disord. 2015 Jan;30(1):4-18. doi: 10.1002/mds.26102. Epub 2014 Dec 9.Mov Disord. 2015.PMID:25491387Review.
- Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum.Lopez A, Muñoz A, Guerra MJ, Labandeira-Garcia JL.Lopez A, et al.Neuroscience. 2001;103(3):639-51. doi: 10.1016/s0306-4522(00)00588-1.Neuroscience. 2001.PMID:11274784
- Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group.Moreau C, et al.Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23.Brain. 2015.PMID:25805645Free PMC article.Clinical Trial.
- Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B.Calabresi P, et al.Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672):20140184. doi: 10.1098/rstb.2014.0184.Philos Trans R Soc Lond B Biol Sci. 2015.PMID:26009763Free PMC article.Review.
Cited by
- Metabolic Pathway Reconstruction Indicates the Presence of Important Medicinal Compounds inCoffea Such as L-DOPA.Cherubino Ribeiro TH, de Oliveira RR, das Neves TT, Santiago WD, Mansur BL, Saczk AA, Vilela de Resende ML, Chalfun-Junior A.Cherubino Ribeiro TH, et al.Int J Mol Sci. 2023 Aug 5;24(15):12466. doi: 10.3390/ijms241512466.Int J Mol Sci. 2023.PMID:37569839Free PMC article.
- Prediction of dyskinesia in Parkinson's disease patients using machine learning algorithms.Leal DAB, Dias CMV, Ramos RP, Brys I.Leal DAB, et al.Sci Rep. 2023 Dec 16;13(1):22426. doi: 10.1038/s41598-023-49617-w.Sci Rep. 2023.PMID:38104147Free PMC article.
- Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.Teleanu RI, Preda MD, Niculescu AG, Vladâcenco O, Radu CI, Grumezescu AM, Teleanu DM.Teleanu RI, et al.Pharmaceutics. 2022 May 4;14(5):987. doi: 10.3390/pharmaceutics14050987.Pharmaceutics. 2022.PMID:35631573Free PMC article.Review.
- A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides.Singh K, Gupta JK, Kumar S, Soni U.Singh K, et al.Curr Protein Pept Sci. 2024;25(7):507-526. doi: 10.2174/0113892037275221240327042353.Curr Protein Pept Sci. 2024.PMID:38561605Review.
- Levodopa Rescues Retinal Function in the Transgenic A53T Alpha-Synuclein Model of Parkinson's Disease.Tran KKN, Wong VHY, Vessey KA, Finkelstein DI, Bui BV, Nguyen CTO.Tran KKN, et al.Biomedicines. 2024 Jan 8;12(1):130. doi: 10.3390/biomedicines12010130.Biomedicines. 2024.PMID:38255235Free PMC article.
References
- Cotzias GC, Papavasiliou PS. Papavasiliou PS. Therapeutic studies of Parkinsonian patients: long term effects of D, L, and L Dopa. Brookhaven National Lab., Upton, NY; 1967 Jan 1
- Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374–9. - PubMed
- Carlsson A, Lindqvist M, Magnusson TO. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957;180:1200. - PubMed
- Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord. 2008;23(Suppl 3):S497–508. - PubMed
- Bell EA, Janzen DH. Medical and ecological considerations of L-dopa and 5-HTP in seeds. Nature. 1971;229:136–7. - PubMed